NCT03007693

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants

A Randomized, Placebo-controlled, Double-blind, Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 71 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the safety and tolerability of JNJ-61393215 after multiple consecutive dose administrations and to characterize the pharmacokinetics (PK) of JNJ-61393215 in plasma after multiple consecutive dose administrations.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-61393215	Participants will receive JNJ-61393215 for 7 days.
DRUG	Placebo	Participants will receive JNJ- 61393215 matching placebo for 7 days.

Timeline

• Start date: 2017-01-01
• Primary completion: 2017-10-01
• Completion: 2017-10-01
• First posted: 2017-01-02
• Last updated: 2025-04-27

Locations

1 site across 1 country: Netherlands